Replies to post #56 on Pharmasset Inc. (fka VRUS)

[surf1944]

7:02AM Pharmasset: PSI-7977 receives fast track designation from the FDA for the treatment of chronic hepatitis C infection (VRUS) 26.81 : Co has received fast track designation from the U.S. Food and Drug Administration for PSI-7977 for the treatment of chronic hepatitis C virus infection. PSI-7977 is an oral uridine nucleotide analog polymerase inhibitor of chronic hepatitis C. Co recently completed dosing in a 28 day Phase 2a trial to evaluate PSI-7977 in combination with Pegasys plus Copegus in treatment-naive patients chronically infected with chronic hepatitis C genotype 1. Co expects to initiate a 12-week Phase 2b study of PSI-7977 in the fourth quarter of 2010.